SCHEMBL9966237

SCHEMBL9966237

CCc1noc(O)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7270467 0.78
SCHEMBL7270462 0.78
SCHEMBL15115461 0.74 CHRM2 (0.43)
SCHEMBL3796925 0.72
SCHEMBL12705 0.72
SCHEMBL2411467 0.72 LCK (0.49)
SCHEMBL11868962 0.70 ALOX5 (0.30)
SCHEMBL13853947 0.70
SCHEMBL91599 0.70
SCHEMBL21872264 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200290963-A1 SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2020-09-17 US disclosed
US-20170037030-A1 AUTOTAXIN INHIBITORS NOVARTIS AG (CH) 2017-02-09 US disclosed
US-20170007614-A1 Autotaxin inhibitors NOVARTIS AG (CH) 2017-01-12 US disclosed
US-20170007614-A1 Autotaxin inhibitors NOVARTIS AG (CH) 2017-01-12 US disclosed
EP-2855464-B1 NITRIC OXIDE DONOR NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2016-10-26 EP disclosed
WO-2015162558-A1 AUTOTAXIN INHIBITORS NOVARTIS AG (CH) 2015-10-29 WO disclosed
EP-2651896-B1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R & D IP LLC (US) 2015-08-12 EP disclosed
WO-2014097151-A2 AUTOTAXIN INHIBITORS NOVARTIS AG (CH) 2014-06-26 WO disclosed
US-8283353-B2 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-09 US disclosed
US-20120213806-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-08-23 US disclosed
US-20120213807-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-08-23 US disclosed
US-20120157383-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-06-21 US disclosed
US-20120157386-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-06-21 US disclosed
US-20100292273-A1 Cannabinoid Receptor Modulators 7TM PHARMA A/S (DK) 2010-11-18 US disclosed
US-20100197683-A1 FUSED RING COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-08-05 US disclosed
EP-1692140-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-12-09 EP disclosed
US-7514427-B2 1,5,6,-substituted-2-oxo-3-cyano-1,6a-diaza-tetrahydro-fluoranthenes as anti-inflective agents TIBOTEC PHARMACEUTICALS, LTD. (IE) 2009-04-07 US disclosed
US-20080167296-A1 1,5,6,-Substituted-2-Oxo-3-Cyano-1,6a-Diaza-Tetrahydro-Fluoranthenes as Anti-Infective Agents TIBOTEC PHARMACEUTICALS LTD. (IE) 2008-07-10 US disclosed
US-3994909-A FUNGICIDES BASF AKTIENGESELLSCHAFT (DT) 1976-11-30 US disclosed